Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.

Stern, Howard M; Padilla, Mary; Wagner, Klaus; Amler, Lukas; Ashkenazi, Avi

Stern, Howard M; Padilla, Mary; Wagner, Klaus; Amler, Lukas; Ashkenazi, Avi.

Affiliation

Stern HM; Departments of Research Pathology, Development Oncology Diagnostics, and Molecular Oncology, Genentech, Inc, South San Francisco, California, USA.

Clin Cancer Res ; 16(5): 1587-96, 2010 Mar 01.

Article in En | MEDLINE | ID: mdl-20179215

Subject(s)

Antineoplastic Agents/therapeutic use; Fucosyltransferases/analysis; Immunohistochemistry/methods; N-Acetylgalactosaminyltransferases/analysis; TNF-Related Apoptosis-Inducing Ligand/therapeutic use; Antibodies, Monoclonal/therapeutic use; Biomarkers, Tumor/analysis; Biomarkers, Tumor/biosynthesis; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/metabolism; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms/drug therapy; Colorectal Neoplasms/metabolism; Enzyme-Linked Immunosorbent Assay; Fucosyltransferases/biosynthesis; Humans; Lung Neoplasms/drug therapy; Lung Neoplasms/metabolism; N-Acetylgalactosaminyltransferases/biosynthesis; Sensitivity and Specificity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunohistochemistry / N-Acetylgalactosaminyltransferases / TNF-Related Apoptosis-Inducing Ligand / Fucosyltransferases / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2010 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google